Bruker (NASDAQ:BRKR) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Bruker (NASDAQ:BRKR) from a hold rating to a buy rating in a research note released on Saturday morning.

Other equities analysts have also issued reports about the company. TD Cowen increased their price objective on Bruker from $43.00 to $45.00 and gave the company a “hold” rating in a research report on Thursday. Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, April 24th. Barclays increased their price target on shares of Bruker from $45.00 to $53.00 and gave the company an “overweight” rating in a research report on Thursday. Guggenheim decreased their price target on shares of Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Finally, Citigroup boosted their price objective on shares of Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bruker presently has an average rating of “Hold” and a consensus target price of $50.54.

Bruker Stock Performance

Bruker stock opened at $44.16 on Friday. Bruker has a fifty-two week low of $28.53 and a fifty-two week high of $56.22. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.87 and a current ratio of 1.55. The stock has a market cap of $6.72 billion, a P/E ratio of -184.00, a price-to-earnings-growth ratio of 2.65 and a beta of 1.12. The firm’s fifty day moving average price is $37.26 and its 200-day moving average price is $42.06.

Bruker (NASDAQ:BRKR) last released its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The business had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $795.62 million. During the same quarter in the prior year, the firm earned $0.47 earnings per share. The firm’s revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities research analysts expect that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were issued a dividend of $0.05 per share. The ex-dividend date was Monday, March 23rd. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker’s dividend payout ratio is currently -83.33%.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the transaction, the vice president directly owned 128,443 shares of the company’s stock, valued at $5,124,875.70. The trade was a 1.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 27.20% of the stock is currently owned by insiders.

Institutional Trading of Bruker

A number of institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its holdings in Bruker by 23.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,341,518 shares of the medical research company’s stock valued at $84,556,000 after buying an additional 448,440 shares during the last quarter. Swiss National Bank grew its holdings in Bruker by 0.5% in the 1st quarter. Swiss National Bank now owns 210,500 shares of the medical research company’s stock worth $7,603,000 after acquiring an additional 1,000 shares during the last quarter. SteelPeak Wealth LLC bought a new stake in Bruker in the 1st quarter worth $875,000. Allspring Global Investments Holdings LLC increased its position in shares of Bruker by 19.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 306,396 shares of the medical research company’s stock valued at $11,055,000 after acquiring an additional 50,955 shares during the period. Finally, Bastion Asset Management Inc. purchased a new position in shares of Bruker in the first quarter valued at about $777,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.